Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics (QNCX) announced that enrollment in its pivotal Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T) has exceeded 75%, with 65 of the targeted 86 participants (ages 6-9) now randomized; all eligible participants have transitioned to the open label extension study. The company anticipates submitting a New Drug Application to the FDA in the second half of 2026, assuming positive trial results for eDSP, a drug/device combination leveraging the company's AIDE technology.

Analysis

Quince Therapeutics (QNCX) has reported significant progress in its pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia (A-T), with enrollment surpassing 75% for the targeted 86 participants in the six to nine-year-old primary analysis population, now totaling 65 individuals. Including older participants, 76 individuals are enrolled, achieving approximately 80% statistical power based on current numbers, a crucial step towards data robustness. The rate of screening and randomization has accelerated following the activation of all study sites, with 108 participants screened to date and a notably low screen failure rate of 10%. A strong indicator of potential tolerability and perceived benefit is that all 37 participants who have completed the main study period to date have opted to transition to the NEAT open-label extension (OLE) study. Quince anticipates submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, contingent upon positive trial outcomes. The FDA has already granted Fast Track designation for eDSP, highlighting its potential to address the high unmet medical need in A-T, a rare neurodegenerative disorder with approximately 4,600 diagnosed U.S. patients and an estimated 5,000 in the U.K. and EU4, and currently no approved treatments. The eDSP system, utilizing Quince's proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology, aims to deliver dexamethasone sodium phosphate within a patient's own red blood cells, potentially offering improved efficacy and reduced toxicity compared to chronic corticosteroid use.

Key Decisions for Investors

• Investors should view the >75% enrollment in the Phase 3 NEAT trial and the 80% statistical powering as a material de-risking event, though final trial success remains paramount.
• The H2 2026 timeline for a potential NDA submission, supported by FDA Fast Track designation, represents a key long-term catalyst, contingent on positive efficacy and safety data from the NEAT study.
• Consider the high patient transition rate (100% to date) to the open-label extension study as a positive qualitative signal regarding eDSP's tolerability and perceived benefit in the A-T patient population.
• Evaluate the potential of Quince's AIDE technology platform beyond A-T, as its novel drug delivery mechanism could be applicable to other rare diseases requiring chronic administration of drugs with toxicity limitations.
• Monitor for further trial updates, including full enrollment and any interim analyses if planned, as these will be critical inflection points for Quince Therapeutics leading up to the primary data readout.